Evidence map›Paper›PMID 36614019›Full record

ReviewInternational journal of molecular sciences2022

Increasing Stress to Induce Apoptosis in Pancreatic Cancer via the Unfolded Protein Response (UPR).

Gehan Botrus, Richard M Miller, Pedro Luiz Serrano Uson Junior, Geoffrey Kannan, Haiyong Han, Daniel D Von Hoff

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06076837 (An Open-label, Phase I Trial With Expansion Cohort of Nab-Paclitaxel + Gemcitabine + Cisplatin + Botensilimab), which is not on this map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06076837 phase1terminatednot on this mapstarted 2025, after this paper: background citation

An Open-label, Phase I Trial With Expansion Cohort of Nab-Paclitaxel + Gemcitabine + Cisplatin + Botensilimab (AGEN1811) + Balsilimab (AGEN2034) + Chloroquine + Celecoxib in Patients With Previously Untreated Metastatic Pancreatic Cancer

TypeinterventionalSponsorHonorHealth Research InstituteRan2025 to 2025Enrolled6ConditionsPancreatic Cancer Metastatic, Pancreatic Adenocarcinoma MetastaticArmsBotensilimab, Balstilimab, Chloroquine Phosphate, Celecoxib, Nab paclitaxel
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Targeting WFS1 overcomes KRASNPJ precision oncology · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Gehan BotrusDepartment of Oncology and Hematology, Emory University, Atlanta, GA 30322, USA.
Richard M MillerDrug Development, HonorHealth Research and Innovation Institute, Scottsdale, AZ 85258, USA.
Pedro Luiz Serrano Uson JuniorCenter for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo 05652-900, Brazil.
Geoffrey KannanDrug Development, LabCorp, Princeton, NJ 08540, USA.
Haiyong HanBasic Research Unit, Pancreatic Cancer Program, Translational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA.
Daniel D Von HoffMolecular Medicine Division, Translational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA.
Translational Genomics Research Institute · USEmory University · USHonorHealth · USHospital Israelita Albert Einstein · BRLabCorp (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High rates of cell proliferation and protein synthesis in pancreatic cancer are among many factors leading to endoplasmic reticulum (ER) stress. To restore cellular homeostasis, the unfolded protein response (UPR) activates as an adaptive mechanism through either the IRE1α, PERK, or ATF6 pathways to reduce the translational load and process unfolded proteins, thus enabling tumor cells to proliferate. Under severe and prolonged ER stress, however, the UPR may promote adaptation, senescence, or apoptosis under these same pathways if homeostasis is not restored. In this review, we present evidence that high levels of ER stress and UPR activation are present in pancreatic cancer. We detail the mechanisms by which compounds activate one or many of the three arms of the UPR and effectuate downstream apoptosis and examine available data on the pre-clinical and clinical-phase ER stress inducers with the potential for anti-tumor efficacy in pancreatic cancer. Finally, we hypothesize a potential new approach to targeting pancreatic cancer by increasing levels of ER stress and UPR activation to incite apoptotic cell death.

Indexed as

Pancreatic NeoplasmsProtein Serine-Threonine KinasesApoptosiseIF-2 KinaseEndoplasmic Reticulum StressEndoribonucleasesHumansUnfolded Protein ResponseeIF-2 KinaseEndoribonucleasesProtein Serine-Threonine Kinasesapoptosisendoplasmic reticulum (ER) stresspancreatic cancerunfolded protein response (UPR)

Identifiers

PMID36614019
PMCPMC9820188
OpenAlexW4313294696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.